Close Menu

CTCs

Myriad has licensed the technology for early detection of breast, colon, and prostate cancers.

The microfluidic chip, called the On-Q-ity Circulating Cancer Capture and Characterization Chip, or C5, uses both antibody affinity and size to filter CTCs from normal blood. In a study comparing C5 and a chip using antibody affinity alone, On-Q-ity's dual capture chip "greatly improved" capture rate over the comparator.

In recent interviews, J&J officials spoke about ongoing work to further develop its technology for circulating tumor cells to include characterization capabilities, and its new center of excellence for companion diagnostics to leverage partnerships with other diagnostic firms.

LabCorp will market the platform to biopharma researchers conducting clinical studies of oncology drugs.

The partners will develop a bench-top platform to isolate and explore the biology of rare cells at the protein, RNA, and DNA levels.

Initial unpublished data from studies employing the method, competitive allele-specific TaqMan PCR, suggest that it can detect single rare mutant alleles in up to a million wild-type sequences with a high degree of specificity.

Researchers from more than a dozen European research institutes and companies announced this week that they are working to develop lab-on-chip technology for detecting circulating tumor cells and disseminated tumor cells in blood.

The company's first test, a FISH-based assay targeting breast cancer, is planned for October and would represent its first product introduction in its 13-year history.

The startup has now raised a total of $26 million in Series A financing to support development of a biomarker-based cancer diagnostic.

Pages

23andMe is offering early customers re-testing on newer chips for a fee, Wired reports.

He Jiankui is no longer affiliated with Direct Genomics Biotechnology, the single molecule sequencing company he founded, Nikkei Asian Review reports.

Newsweek writes about the hopes for precision medicine in cancer, but also challenges getting it to patients.

In Genome Research this week: genomic architecture of glioblastoma, predictive computational approach to estimate SNP fitness, and more.